Y-mAbs Therapeutics (YMAB) Stock Forecast & Price Target

$11.14 -0.45 (-3.88%)

(As of 11/15/2024 ET)

Y-mAbs Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 8 Analyst Ratings

Sell
1

Hold
0

Buy
7

Based on 8 Wall Street analysts who have issued ratings for Y-mAbs Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 8 analysts, 1 has given a sell rating, 6 have given a buy rating, and 1 has given a strong buy rating for YMAB.

Consensus Price Target

$21.14
89.79% Upside

According to the 8 analysts' twelve-month price targets for Y-mAbs Therapeutics, the average price target is $21.14. The highest price target for YMAB is $26.00, while the lowest price target for YMAB is $11.00. The average price target represents a forecasted upside of 89.79% from the current price of $11.14.

YMAB Analyst Ratings Over Time

Type	Current Forecast 11/19/23 to 11/18/24	1 Month Ago 10/20/23 to 10/19/24	3 Months Ago 8/21/23 to 8/20/24	1 Year Ago 11/19/22 to 11/19/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	4 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	4 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$21.14	$21.14	$19.38	$11.71
Forecasted Upside	89.79% Upside	46.32% Upside	43.41% Upside	115.73% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

[625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

YMAB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

YMAB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Y-mAbs Therapeutics Stock vs. The Competition

Type	Y-mAbs Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.88	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	89.79% Upside	28,621.01% Upside	9.87% Upside
News Sentiment Rating	Positive News See Recent YMAB News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/18/2024	Oppenheimer 3 of 5 stars		Initiated Coverage	Outperform	$23.00	+106.46%
11/15/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00	+102.76%
9/10/2024	Wedbush 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$23.00 ➝ $23.00	+72.03%
9/9/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Watsek Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00 ➝ $20.00	+44.20%
8/13/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Newman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/13/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Underweight ➝ Underweight	$12.00 ➝ $11.00	+10.55%
Has Trump Finally Gone Too Far? (Ad) Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news. Register For The Webinar To Discover
8/13/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$26.00 ➝ $25.00	+151.26%
6/28/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Germino Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00	+70.32%
8/22/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Underweight ➝ Underweight	$8.00 ➝ $7.00	+14.94%
5/15/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$6.00 ➝ $12.00	+33.48%
4/3/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
1/5/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 09:34 AM ET.

YMAB Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Y-mAbs Therapeutics is $21.14, with a high forecast of $26.00 and a low forecast of $11.00.
: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last twelve months. There is currently 1 sell rating, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" YMAB shares.
: According to analysts, Y-mAbs Therapeutics's stock has a predicted upside of 89.79% based on their 12-month stock forecasts.
: Y-mAbs Therapeutics has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, Oppenheimer, and Wedbush in the past 90 days.
: Analysts like Y-mAbs Therapeutics more than other "medical" companies. The consensus rating score for Y-mAbs Therapeutics is 2.88 while the average consensus rating score for "medical" companies is 2.80. Learn more on how YMAB compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

📉 Warning: Market Crash Predicted - Secure Your Savings (Ad)

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>

This page (NASDAQ:YMAB) was last updated on 11/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Y-mAbs Therapeutics (YMAB) Stock Forecast & Price Target